China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its pipeline drug candidate cleviprex. The company’s first nanoemulsion, cleviprex, is a dihydropyridine calcium channel blocker being developed to treat hypertension when oral antihypertensive drugs are not applicable or cannot achieve satisfactory results.
Mechanism and Application
Cleviprex is an innovative oil-in-water emulsion administered by intravenous infusion. It features rapid onset and a short half-life, making it suitable for patients who require immediate blood pressure reduction. The product is designed to reduce arterial blood pressure effectively, providing a valuable option for patients in critical situations where oral medications are insufficient or not feasible.
Future Outlook
The initiation of the clinical study for cleviprex marks a significant step forward in CSPC Pharmaceutical Group’s efforts to expand its therapeutic offerings in the hypertension space. With its unique nanoemulsion formulation and rapid-action mechanism, cleviprex has the potential to address significant unmet needs in the treatment of hypertension. CSPC’s ongoing research and development efforts underscore its commitment to improving patient outcomes through innovative therapies.-Fineline Info & Tech
